Motus GI Holdings, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019257 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.944M	$8.648M
YoY Change	-42.83%	-57.48%
Cash & Equivalents	$4.900M	$8.600M
Short-Term Investments
Other Short-Term Assets	$497.0K	$1.093M
YoY Change	-54.53%	-18.86%
Inventory	$479.0K	$798.0K
Prepaid Expenses
Receivables	$81.00K	$52.00K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$5.750M	$10.26M
YoY Change	-43.94%	-54.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$897.0K	$1.237M
YoY Change	-27.49%	-38.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$13.00K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$1.316M	$1.974M
YoY Change	-33.33%	-2.37%
TOTAL ASSETS
Total Short-Term Assets	$5.750M	$10.26M
Total Long-Term Assets	$1.316M	$1.974M
Total Assets	$7.066M	$12.23M
YoY Change	-42.23%	-49.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.495M	$1.472M
YoY Change	1.56%	-26.1%
Accrued Expenses	$116.0K	$248.0K
YoY Change	-53.23%	-16.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.632M	$2.611M
YoY Change	-37.5%	141.09%
Total Short-Term Liabilities	$3.309M	$4.378M
YoY Change	-24.42%	29.56%
LONG-TERM LIABILITIES
Long-Term Debt	$669.0K	$3.904M
YoY Change	-82.86%	-62.32%
Other Long-Term Liabilities	$21.00K	$1.128M
YoY Change	-98.14%	-45.69%
Total Long-Term Liabilities	$669.0K	$3.904M
YoY Change	-82.86%	-68.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.309M	$4.378M
Total Long-Term Liabilities	$669.0K	$3.904M
Total Liabilities	$3.999M	$13.32M
YoY Change	-69.97%	-15.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.3M	-$145.7M
YoY Change	7.28%
Common Stock	$1.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.067M	-$1.085M
YoY Change
Total Liabilities & Shareholders Equity	$7.066M	$12.23M
YoY Change	-42.23%	-49.92%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2024Q1	us-gaap	Assets Assets	7066000	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1495000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	116000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1632000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3309000	usd
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001686850
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2024Q1	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory		usd
CY2024Q1	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation		usd
CY2023Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount		usd
CY2024Q1	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation		usd
CY2024Q1	MOTS	Impairment Of Inventory ImpairmentOfInventory		usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023Q1	MOTS	Issuance Of Warrants Upon Settlement Of Placement Agent Warrant Obligation IssuanceOfWarrantsUponSettlementOfPlacementAgentWarrantObligation		usd
CY2023Q1	MOTS	Noncash Issuance Costs From Warrant Issuance NoncashIssuanceCostsFromWarrantIssuance		usd
CY2024Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2023Q1	MOTS	Financing Fees Incurred But Unpaid At Period End FinancingFeesIncurredButUnpaidAtPeriodEnd		usd
CY2024Q1	MOTS	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation		usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-38389
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Motus GI Holdings, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4042793
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 East Broward Boulevard
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33301
CY2024Q1	dei	City Area Code CityAreaCode	(954)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	541 8000
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MOTS
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5768876	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4944000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4958000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	81000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	76000	usd
CY2024Q1	MOTS	Inventories Current InventoriesCurrent	228000	usd
CY2023Q4	MOTS	Inventories Current InventoriesCurrent	245000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	497000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	478000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	5750000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5757000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	992000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	210000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2023Q4	us-gaap	Assets Assets	7223000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1842000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	169000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	66000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	226000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	91000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	108000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1033000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3270000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	5000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	16000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	669000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1239000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3999000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4536000	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5210876	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5210876	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1547042	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1547042	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	159397000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	156905000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156331000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-154218000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3067000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2687000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7066000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7223000	usd
CY2024Q1	us-gaap	Revenues Revenues	64000	usd
CY2023Q1	us-gaap	Revenues Revenues	56000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	12000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	9000	usd
CY2023Q1	MOTS	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	165000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	455000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1454000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	151000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	842000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1472000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1945000	usd
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	2090000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	4415000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2026000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4359000	usd
CY2023Q1	MOTS	Gain Loss On Changes In Fair Value Of Contingent Royalty Obligation GainLossOnChangesInFairValueOfContingentRoyaltyObligation	-220000	usd
CY2024Q1	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	80000	usd
CY2023Q1	MOTS	Finance Income Expense Net FinanceIncomeExpenseNet	239000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-7000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-8000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2113000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2024Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	5508000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7621000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4386000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.25
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.25
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-13.81
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-13.81
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-13.81
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-13.81
CY2024Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	8613204	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8613204	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	317547	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	317547	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2687000	usd
CY2024Q1	MOTS	Adjustments To Additional Paid In Capital Issuance Of Warrants Upon Settlement Of Placement Agent Warrant Obligation AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsUponSettlementOfPlacementAgentWarrantObligation	154000	usd
CY2024Q1	MOTS	Financing Fees FinancingFees	504000	usd
CY2024Q1	MOTS	Stock Issued During Period Value Issuance Of Common Shares Upon Exercise Of Warrants StockIssuedDuringPeriodValueIssuanceOfCommonSharesUponExerciseOfWarrants	2268000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	71000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2113000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	3067000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q1	MOTS	Stock Issuance Costs StockIssuanceCosts	19000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1085000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1085000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2113000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	95000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	117000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	62000	usd
CY2023Q1	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	220000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	71000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	222000	usd
CY2023Q1	MOTS	Impairment Of Inventory ImpairmentOfInventory	165000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	55000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	73000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-17000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	19000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	312000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-88000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-472000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-60000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-74000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2023000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4802000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2712000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	655000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	328000	usd
CY2024Q1	MOTS	Payments For Equity Financing Fees PaymentsForEquityFinancingFees	375000	usd
CY2023Q1	MOTS	Payments For Equity Financing Fees PaymentsForEquityFinancingFees	19000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2009000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-553000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5394000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4958000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14042000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4944000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8648000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	81000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	246000	usd
CY2024Q1	MOTS	Issuance Of Warrants Upon Settlement Of Placement Agent Warrant Obligation IssuanceOfWarrantsUponSettlementOfPlacementAgentWarrantObligation	154000	usd
CY2024Q1	MOTS	Noncash Issuance Costs From Warrant Issuance NoncashIssuanceCostsFromWarrantIssuance	60000	usd
CY2023Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	14000	usd
CY2024Q1	MOTS	Financing Fees Incurred But Unpaid At Period End FinancingFeesIncurredButUnpaidAtPeriodEnd	69000	usd
CY2023Q1	MOTS	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation	35000	usd
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_801_eus-gaap--NatureOfOperations_zdstQYEHdb0h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82A_zZAOjJC1rSP6">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to improve visualization to provide better-quality exams and avoid delayed or canceled procedures.. The Company received 510(k) clearance in October 2023 from the FDA for the Pure-Vu EVS System for use in the upper GI tract and Gen 4 Colon and has commenced limited market introduction of these products in over the last few months. Both devices leverage the same workstation and feature key enhancements such as a larger and more powerful suction channel, more efficient irrigation jets, a smaller profile distal tip that offers enhanced flexibility during insertion, enhanced navigation and a much easier bed side set up. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2023Q4	MOTS	Inventory Current InventoryCurrent	245000	usd
CY2024Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2023Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	251000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-2100000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2000000.0	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4900000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-156300000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_zMJhPqGw5ggd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zIV8YM2quOSa">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On November 2, 2023, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-15 (the “2023 Reverse Stock Split”).
CY2024Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	5508000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	165000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	451000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	487000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	196000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	756000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	541000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	728000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	728000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	479000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	496000	usd
CY2024Q1	MOTS	Inventory Current InventoryCurrent	228000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3336000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3336000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2439000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2344000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	897000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	992000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	95000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	117000	usd
CY2024Q1	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	-10000	usd
CY2023Q1	MOTS	Operating Lease Cost Net OperatingLeaseCostNet	16000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	41000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	25000	usd
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	47000	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	40000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	78000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	81000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	210000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	116000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	169000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	137000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	196000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M4D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0724	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.073	pure
CY2024Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	67000	usd
CY2023Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	49000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5743000	usd
CY2024Q1	us-gaap	Debt Default Longterm Debt Amount DebtDefaultLongtermDebtAmount	5681000	usd
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	62000	usd
CY2024Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0175	pure
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	55000	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	246000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	30000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	62000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	85000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	308000	usd
CY2024Q1	MOTS	License Fees LicenseFees	67000	usd
CY2023Q1	MOTS	License Fees LicenseFees	49000	usd
CY2024Q1	MOTS	Number Of Shares Issued On Settlement Of Royalty Payment NumberOfSharesIssuedOnSettlementOfRoyaltyPayment	46768	shares
CY2023Q1	MOTS	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	220000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	71000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	222000	usd
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35000	shares
CY2024Q1	MOTS	Potential Cash Bonus Payments PotentialCashBonusPayments	900000000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-019257-index-headers.html	Edgar Link	pending
0001493152-24-019257-index.html	Edgar Link	pending
0001493152-24-019257.txt	Edgar Link	pending
0001493152-24-019257-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex31-3.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mots-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mots-20240331_def.xml	Edgar Link	unprocessable
mots-20240331_lab.xml	Edgar Link	unprocessable
mots-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
mots-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Motus GI Holdings, Inc.

2024 Q2 Form 10-Q Financial Statement

#000149315224019257 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission